杂志简称：clin drug invest
中文译名：《临床药物研究》
收录属性：scie（2024版）, 目次收录（维普）, 目次收录（知网）,英文期刊,
自引率：1.10%
投稿方向：医学、pharmacology & pharmacy药学
SCI/E期刊基本信息
出版周期：月刊 地区：新西兰
中科院分区：4区
是否TOP：非TOP期刊
是否综述：非综述期刊
是否OA：非OA期刊
国际标准刊号：ISSN 1173-2563；EISSN 1179-1918
杂志语言：英语
出版国家：新西兰
杂志官网 联系方式
出版地址：5 THE WAREHOUSE WAY,NORTHCOTE,NEW ZEALAND,AUCKLAND,0627
杂志邮箱：
投稿网址：https://www.editorialmanager.com/cdia/
杂志官方网址：https://www.springer.com/journal/40261
出版商网址：http://www.adisonline.info
杂志投稿要求
期刊相关咨询邮箱【杂志社官方网站信息】
Contact the journal
Submission-related enquiries
Queries about submission issues, peer review process, or the status of your manuscript should be sent to Kiruthika Gunaselvam (kiruthika.gunaselvam@springernature.com).
Production-related enquiries
Queries about accepted manuscripts in production or post-publication corrections should be sent to Anburaj Sundaram (Anburaj.Sundaram@springer.com).
Rights and Permissions enquiries
For permission requests to reuse or reprint content, please follow the link ‘Rights and permissions’ on the relevant article page. For other queries, contact journalpermissions@springernature.com.
Publication-related enquiries
Queries related to journal publishing should be sent to Jasbir Singh (jasbir.singh@springer.com).
投稿须知【杂志社官方网站信息】
Clinical Drug Investigation
Submission guidelines
Instructions for Authors
Please read these instructions in conjunction with the "Additional Information for Authors" document. This document, together with other useful submission documentation, can be found by following the "Important Information for Authors" link:
Important Information for Authors
Types of Papers
Please note:
The word counts given below do not include the abstract, references, figure legends or table captions.
Review Article. Word count up to 8000. Provides an authoritative, balanced, comprehensive, fully referenced and critical review of the literature.
Current Opinion. Word count approximately 1500 to 3000. Places an area in perspective given that it is of current international interest and a consensus has not yet been reached; therefore, the arguments presented may be controversial, but at the same time must be balanced and rational.
Leading Article. Word count up to 4000. Provides a short, balanced overview of the current state of development of an emerging area.
Systematic Review. Word count up to 10,000. Collates all empirical evidence that fits pre-specified eligibility criteria to answer a specific research question. It uses explicit, systematic methods that are selected with a view to minimizing bias, thus providing reliable findings from which conclusions can be drawn and decisions made. Please follow the reporting guidelines of PRISMA.
Original Research. This should be submitted as an Original Research Article (word count up to 4000 plus any Electronic Supplementary Material), following the reporting guidelines of CONSORT for randomized controlled trials, and STROBE for purely observational studies Reports of studies that have investigated original approaches to clinical management but that are smaller in scale and, thus, may report pilot data warranting further investigation, may also be considered for publication; such articles should be submitted as Short Communications.
Case Report. Word count up to 1800 with a short (up to 150 word) abstract. Case reports on new or unusual events in one or more patients that expand the knowledge about common disease states or provide significant information about drug efficacy, adverse reactions, or interactions will be considered.
Letter to the Editor. Word count up to 1000. Comment on an article published recently in the journal; a response to the comments would normally be sought from the authors of the original article and published in the same issue, where possible.
Editorial/Commentary. Word count up to 1500. A brief opinion piece on a current topic of high interest.
Editorial Procedure
Internal Review by Editorial Staff: The journal editor will perform an initial appraisal of each manuscript. If your paper has been peer reviewed by another journal as part of a prior submission, the journal editor will also assess any previous editorial/referee comments and how these have been dealt with as part of the appraisal process. If your manuscript is considered unsuitable for the journal to which it has been submitted, it may be assessed for suitability for publication in other Adis journals by appropriate editors. However, it will not be progressed to external peer review for an alternative journal without your permission.
External Peer Review: Peer reviewer identities are kept confidential, but author identities are known to the reviewers. Peer reviewers are asked to disclose potential conflicts of interests that may affect their ability to provide an unbiased review of an article. The majority of manuscripts will require some degree of revision following peer review before they can be accepted for publication. The final decision on acceptability for publication lies with the journal editor.
Copy Editing: All accepted manuscripts are copy edited. This process addresses general publishing considerations, such as layout of tables and figures, housestyle and clarity of expression. Authors will receive proofs following editing for their approval and sign off. It should be noted that the responsibility for checking the technical accuracy and consistency of data within the article rests with the authors.